Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma

International Journal of Laboratory Hematology

Volumn 30, Issue 4, 2008, Pages 292-299

  Hashino, S ^a   Morioka, M ^b   Irie, T ^b   Shiroshita, N ^b   Kawamura, T ^c   Suzuki, S ^c   Iwasaki, H ^d   Umehara, S ^d   Kakinoki, Y ^e   Kurosawa, M ^f   Kahata, K ^f   Izumiyama, K ^g   Kobayashi, H ^g   Onozawa, M ^a   Takahata, M ^a   Fujisawa, F ^a   Kondo, T ^a   Asaka, M ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

^c HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^d Sapporo Kousei Hospital   (Japan)

^e ASAHIKAWA CITY HOSPITAL   (Japan)

^f HOKKAIDO CANCER CENTER   (Japan)

^g Obihiro Kousei Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PIRARUBICIN; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SEROTONIN ANTAGONIST; VINCRISTINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; ECONOMICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; CROSS-OVER STUDIES; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 53449098791     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00955.x     Document Type: Article

References (17)

1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P. & Gisselbrecht C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 346, 235-242.
2. Donnelly G.B., Glassman J., Long C., Torre P., Straus D.J., O'Brien J.P., Bertino J., Moskowitz C.H., Zelenetz A.D. & Portlock C.S. (2000) Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leukemia and Lymphoma 39, 67-75.
3. Doorduijn J.K., van der Holt B., van Imhoff G.W., van der Hem K.G., Kramer M.H., van Oers M.H., Ossenkoppele G.J., Schaafsma M.R., Verdonck L.F., Verhoef G.E., Steijaert M.M., Buijt I., Uyl-de Groot C.A., van Agthoven M., Mulder A.H. & Sonneveld P. (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non- Hodgkin's lymphoma. Journal of Clinical Oncology 15, 3041-3050.
4. Doorduijn J.K., Buijt I., van der Holt B., van Agthoven M., Sonneveld P. & Uylde Groot C.A. (2004) Economic evaluation of prophylactic granulocyte colonystimulating factor during chemotherapy in elderly patients with aggressive non- Hodgkin's lymphoma. Haematologica 89, 1109-1117.
5. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Jr & Miller T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 328, 1002-1006.
6. Garcia-Carbonero R., Mayordomo J.I., Tornamira M.V., Lopez-Brea M., Rueda A., Guillem V., Arcediano A., Yubero A., Ribera F., Gomez C., Trea A., Perez- Garcia J.L., Lumbreras C., Hornedo J., Cortes-Funes H. & Paz-Ares L. (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of National Cancer Institute 93, 31-38.
7. Hara T., Tsurumi H., Kasahara S., Kanemura N., Yoshikawa T., Goto N., Kojima Y., Yamada T., Sawada M., Takahashi T., Oyama M., Tomita E. & Morikawa H. (2005) Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non- Hodgkin's lymphoma with higher costeffectiveness. International Journal of Hematology 82, 430-436.
8. Juan O., Campos J.M., Caranara V., Sanchez J.J., Casan R. & Alberola V. (2001) A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia. Supportive Care in Cancer 9, 241-246.
9. Kakinoki Y., Kubota H. & Yamamoto Y. (2004) CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma. International Journal of Hematology 79, 55-62.
10. Lyman G.H., Morrison V.A., Dale D.C., Crawford J., Delgado D.J. & Fridman M. (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgikin's lymphoma receiving CHOP chemotherapy. Leukemia and Lymphoma 44, 2069-2076.
11. Martin-Christin F. (2001) Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 12, 185-191.
12. Niitsu N., Hayama M., Okamoto M., Khori M., Higashihara M., Tamaru J. & Hirano M. (2004) Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clinical Cancer Research 10, 4077-4082.
13. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N. & Anderson D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclobal antibody to CD20. Blood 83, 435-445.
14. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Somerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J. & Wolff A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 24, 3187-3205.
15. Toner G.C., Shapiro J.D., Laidlaw C.R., Rischin D., Millward M.J., Wolf M., Januszewicz H., Mitchell S.V., Curran A.C., Matthews J.P. & Bishop J.F. (1998) Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. Journal of Clinical Oncology 16, 3874-3879.
16. WHO Expert Committee on Biological Standardization (1994a) Forty-fourth Report. World Health Organization Technical Report Series 840, 1-218.
17. WHO Expert Committee on Biological Standardization (1994b) Forty-third Report. World Health Organization Technical Report Series 848, 1-90.